NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/13/2023
Back to search
Official data from USPTO
SAJAZIR
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
06/13/2023
Trademark type
Word
Nice classes
5
Filing date
01/12/2021
Registration date
06/13/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/13/2023
Last transaction
06/13/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/23/2022
First use in commerce
09/23/2022
Drawing code
4
Owner type
99
Owner location
Cambridge, GB
Examiner
BRACEY, KAREN
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Cycle Pharmaceuticals Ltd.
Representatives
Mary Frances Love MUNCY, GEISSLER, OLDS & LOWE, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical agents for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; pharmaceutical preparations for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; pharmaceuticals for the treatment of hereditary angioedema all in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; Veterinary preparations for treatment of intestinal bacteria; veterinary preparationsantioxidants; veterinary preparationspain relief medications; veterinary preparations for medical treatment of chronic illnesses; veterinary preparations for treatment of viral diseases; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; dietary supplements for humans and animals; supplements for the treatment of hereditary angioedema; supplements for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; food for babies; medical dressings; plasters for medical purposes; material for stopping teethdental wax; disinfectants; preparations for destroying vermin; fungicidesherbicides; biological preparations for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gels and transdermal patches; chemical preparations for the medical treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gels and transdermal patches; Drug delivery agents consisting of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents for use in pharmaceutical preparationsdrugs and medicines for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; medical drugs for the treatment of rare diseasesin particular for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; enzyme preparations for medical purposesenzyme preparations for the treatment of hereditary angioedemamedical enzyme preparations in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; enzyme preparations for veterinary purposes; medicinal preparations for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; medicines for the treatment of hereditary angioedemaall in the form of liquidstopical solutionsliquid suspensionssyrupsdropscapsulestabletscapletspowderscompressed tabletsdispersible tabletsinhaled vaporsgasesmiststopical creams and gelstransdermal patches; Medical and veterinary preparations and articlespre-filled syringes containing a bradykinin B2 receptor antagonist for medical purposes; Pharmaceuticals and natural remedy preparationsfor use in the treatment and management of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist; syringes sold filled with a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema; single-use pre-filled syringes containing a bradykinin B2 receptor antagonist for subcutaneous injections in the treatment of acute attack of hereditary angioedema
Publications
History of USPTO decisions and trademark events.
31 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/13/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/09/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/08/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/04/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/04/2023
IUAF
USE AMENDMENT FILED
04/18/2023
EISU
TEAS STATEMENT OF USE RECEIVED
04/18/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/18/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/23/2022
PUBO
PUBLISHED FOR OPPOSITION
08/23/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/03/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/15/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/14/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/14/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
07/14/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
02/01/2022
GNFR
FINAL REFUSAL E-MAILED
02/01/2022
CNFR
FINAL REFUSAL WRITTEN
02/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/20/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/20/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/20/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/05/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/05/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/05/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/28/2021
GNRT
NON-FINAL ACTION E-MAILED
07/28/2021
CNRT
NON-FINAL ACTION WRITTEN
07/28/2021
DOCK
ASSIGNED TO EXAMINER
07/21/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/12/2021
NWAP
NEW APPLICATION ENTERED
01/15/2021
Continuous trademark protection
Get notified about every new filing that threatens SAJAZIR or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.